Salazar JJ, León-Quintero GI, Salazar EN, Juárez-Durán ÉR, Vega ME

Language: Spanish
References: 18
Page: 198-201
PDF size: 204.92 Kb.

ABSTRACT

Bullous pemphigoid is an autoimmune bullous disease caused by cellular and humoral responses against hemidesmosome antigens bp180 and bp230. In the other hand, diabetes mellitus is an important public health problem in Mexico.
The objective of this paper is to report the therapeutic effectiveness of oral doxycycline and topical clobetasol in five diabetes patients with bullous pemphigoid. According to our results, we conclude that this combination is an adequate therapeutic option instead of systemic corticosteroids in patients with bullous pemphigoid and diabetes mellitus.

REFERENCES

1. Harberle S, Wei X, Bieber K, Goletz S, Ludwing R, Schmidt E, Enk A y Hadaschik E, Regulatory t-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease, J Allergy Clin Immunol 2018; 142:1831-42.

2. Heymann W, Bullae for you: the increasing importance and implications of drug-induced bullous pemphigoid, J Am Acad Dermatol 2018; 79:1026-7.

3. Kridin K, Shihade W y Bergman R, Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis, Acta Derm Venereol 2019; 99:72-7.

4. Williams H, Wojnarowska F, Kirtschig G, Mason J, Godec T, Schmidt E, Chalmers J, Childs M, Walton S, Harman K, Chapman A, Whitman D y Nunn A, Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomized controlled trial, Lancet 2017; 389(100079):1630-8.

5. Lucariello R, Villablanca S, Mascaró J y Martin R, Association between bullous pemphigoid and malignancy, Australasian J Dermatology 2018; 59:253-60.

6. Grantham H, Stocken D y Reynolds N, Doxycycline: a first-line treatment for bullous pemphigoid?, The Lancet 2017; 387:1586-88.

7. Kalinska-Bienias A, Kowalczyk E, Jagielski P, Kowalewski C y Wozniak K, Tetracycline, nicotinamide, and lesionally administered clobetasol as a therapeutic option to prednisone in patients with bullous pemphigoid: a comparative, retrospective analysis of 106 patients with longterm follow-up, Int J Dermatol 2019; 58:172-7.

8. Cardones AR y Hall R, Doxycycline and the treatment for bullous pemphigoid: what outcomes are most, Br J Dermatol 2017; 177:1145-7.

9. Bello-Chavolla O, Rojas-Martínez R, Aguilar-Salinas C y Hernández-Ávila M, Epidemiology of diabetes mellitus in Mexico, Nutr Rev 2017; 75:4-12.

10. Skandalis K, Spirova M, Gaitanis G, Tsartsakaris A y Bassukas ID, Druginduced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-iv inhibitors plus metformin, J Eur Acad Dermatol Venereol 2012; 26:249-53.

11. Mendoza F, Martín-Gutiérrez F, Ríos-Martín J y Camacho-Martínez F, Three cases of bullous pemphigoid associated with dipeptidyl peptidase- 4 inhibitors: one due to linagliptin, Dermatology 2016; 232:249-53.

12. Varpuluoma O, Forsti AK, Jokelainen J, Turpeinen M, Timonen M, Tasanen K y Huilaja L, Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a finish nationwide case-control study, J Am Acad Dermatol 2018; 79:1034-8.

13. Reolid A, Muñoz-Aceituno E, Rodríguez-Jiménez P, González-Rojano E, Llamas-Velasco M, Fraga J y Daudén E, Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database, Int J Dermatol 2019; 59:197-206.

14. Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA y Feldmeyer L, Dipeptidyl peptidase iv inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland, J Am Acad Dermatol 2018; 78:1090-6.

15. Arai M, Shirakawa J, Konishi H, Sagawa N y Terauchi Y, Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors. A disproportionality analysis based on the Japanese adverse drug event report database, Diabetes Care 2018; 41:e130-2.

16. Ahmed A, Shetty S, Kaberi S y Spigelman Z, Treatment of recalcitrant bullous pemphigoid (bp) with a novel protocol: a retrospective study with a 6 year follow up, J Am Acad Dermatol 2016; 74:700-8.

17. Rozenblat M, Halaj A, Rozenblat T, Fisher S, Sah M, Dodiuk-Gad R y Ziv M, Mortality and risk factors among Israeli bullous pemphigoid patients, Arch of Dermatol Research 2019; 311:19-27.

18. Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y y Feldman R, Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients, J Am Acad Dermatol 2019; 81:179-86.